Hubei Hongyuan Pharmaceutical Technology Balance Sheet Health
Financial Health criteria checks 5/6
Hubei Hongyuan Pharmaceutical Technology has a total shareholder equity of CN¥4.4B and total debt of CN¥338.9M, which brings its debt-to-equity ratio to 7.7%. Its total assets and total liabilities are CN¥5.6B and CN¥1.2B respectively. Hubei Hongyuan Pharmaceutical Technology's EBIT is CN¥59.3M making its interest coverage ratio -3.1. It has cash and short-term investments of CN¥2.0B.
Key information
7.7%
Debt to equity ratio
CN¥338.89m
Debt
| Interest coverage ratio | -3.1x |
| Cash | CN¥2.02b |
| Equity | CN¥4.39b |
| Total liabilities | CN¥1.25b |
| Total assets | CN¥5.64b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 301246's short term assets (CN¥3.1B) exceed its short term liabilities (CN¥875.9M).
Long Term Liabilities: 301246's short term assets (CN¥3.1B) exceed its long term liabilities (CN¥371.9M).
Debt to Equity History and Analysis
Debt Level: 301246 has more cash than its total debt.
Reducing Debt: 301246's debt to equity ratio has reduced from 47.8% to 7.7% over the past 5 years.
Debt Coverage: 301246's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 301246 earns more interest than it pays, so coverage of interest payments is not a concern.